Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilonacept in Recurrent Pericarditis
NCT03737110Phase 3Completed
- Sponsor
- Kiniksa Pharmaceuticals
- Start
- Jan 2019
- Primary completion
- May 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 4
01
Overview
A Phase 3 trial of rilonacept in recurrent pericarditis, sponsored by Kiniksa Pharmaceuticals. Started Jan 2019; status: completed.
02
Drugs
rilonacept
03
Conditions
recurrent pericarditis
Beyond the preview
Go deeper on NCT03737110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03737110.